Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 4,900 shares, a drop of 52.9% from the January 31st total of 10,400 shares. Based on an average daily volume of 61,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, D. Boral Capital initiated coverage on shares of Estrella Immunopharma in a research note on Tuesday, February 18th. They issued a “buy” rating and a $16.00 price objective on the stock.

Estrella Immunopharma Price Performance

ESLA stock traded up $0.07 during midday trading on Friday, hitting $1.03. 35,322 shares of the stock traded hands, compared to its average volume of 79,477. The firm has a market cap of $37.26 million, a P/E ratio of -3.96 and a beta of 0.41. The stock’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $1.09. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $3.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,418 shares of the company’s stock after purchasing an additional 16,862 shares during the period. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.